|Videos|June 4, 2018

Identifying Variables Predictive of HIV Acquisition in Electronic Health Records

Douglas Krakower, MD, discusses which variables in electronic health records could be used to identify candidates for pre-exposure prophylaxis.

Douglas Krakower, MD, assistant professor of medicine at Harvard Medical School, discusses which variables in electronic health records could be used to identify candidates for pre-exposure prophylaxis.

Interview Transcript (modified slightly for readability):

“In terms of the variables that we identified in terms of the electronic health record that would be predictive of HIV acquisition, we initially put in a large number of variables into a machine learning model, 168 different variables; these are from a number of different categories including diagnosis codes, registration data, like demographics such as race, ethnicity, age, prescription information, and laboratory patterns in terms of testing and results.

All of these different categories provided complementary information with the machine learning methodology that we used the machine learning program has an internal variable selection procedure, so, it actually figures out which of those many variables are the ones that are most predictive and then it retains those in a final predicative model. In the final model it drew from each of those different categories that I mentioned, such as prescriptions, diagnosis codes, demographic information, to try and come up with a way to identify people who are candidates for pre-exposure prophylaxis (PrEP).”


Related to this article

Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.